vs
安霸（AMBA）与Beam Therapeutics Inc.（BEAM）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是安霸的1.1倍（$114.1M vs $108.5M），Beam Therapeutics Inc.净利率更高（214.1% vs -13.9%，领先228.0%），Beam Therapeutics Inc.同比增速更快（279.5% vs 31.2%），安霸自由现金流更多（$31.4M vs $-87.0M）
安霸是美国无晶圆厂半导体设计企业，专注于低功耗高清、超高清视频压缩、图像处理及计算机视觉处理器研发。其芯片产品广泛应用于视频安防、高级驾驶辅助系统、电子后视镜、行车记录仪、驾驶舱内监测、自动驾驶、机器人等多元人机视觉场景。
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
AMBA vs BEAM — 直观对比
营收规模更大
BEAM
是对方的1.1倍
$108.5M
营收增速更快
BEAM
高出248.3%
31.2%
净利率更高
BEAM
高出228.0%
-13.9%
自由现金流更多
AMBA
多$118.4M
$-87.0M
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $108.5M | $114.1M |
| 净利润 | $-15.1M | $244.3M |
| 毛利率 | 59.6% | — |
| 营业利润率 | -15.0% | -15.3% |
| 净利率 | -13.9% | 214.1% |
| 营收同比 | 31.2% | 279.5% |
| 净利润同比 | 37.2% | 370.4% |
| 每股收益（稀释后） | $-0.35 | $2.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMBABEAM
| Q4 25 | $108.5M | $114.1M | ||
| Q3 25 | $95.5M | — | ||
| Q2 25 | $85.9M | — | ||
| Q1 25 | $84.0M | — | ||
| Q4 24 | $82.7M | — | ||
| Q3 24 | $63.7M | — | ||
| Q2 24 | $54.5M | — | ||
| Q1 24 | $51.6M | — |
净利润AMBABEAM
| Q4 25 | $-15.1M | $244.3M | ||
| Q3 25 | $-20.0M | — | ||
| Q2 25 | $-24.3M | — | ||
| Q1 25 | $-20.2M | — | ||
| Q4 24 | $-24.1M | — | ||
| Q3 24 | $-34.9M | — | ||
| Q2 24 | $-37.9M | — | ||
| Q1 24 | $-60.6M | — |
毛利率AMBABEAM
| Q4 25 | 59.6% | — | ||
| Q3 25 | 58.9% | — | ||
| Q2 25 | 60.0% | — | ||
| Q1 25 | 60.0% | — | ||
| Q4 24 | 60.6% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 59.8% | — |
营业利润率AMBABEAM
| Q4 25 | -15.0% | -15.3% | ||
| Q3 25 | -23.0% | — | ||
| Q2 25 | -30.1% | — | ||
| Q1 25 | -30.2% | — | ||
| Q4 24 | -30.9% | — | ||
| Q3 24 | -56.9% | — | ||
| Q2 24 | -72.4% | — | ||
| Q1 24 | -80.8% | — |
净利率AMBABEAM
| Q4 25 | -13.9% | 214.1% | ||
| Q3 25 | -20.9% | — | ||
| Q2 25 | -28.3% | — | ||
| Q1 25 | -24.1% | — | ||
| Q4 24 | -29.1% | — | ||
| Q3 24 | -54.8% | — | ||
| Q2 24 | -69.6% | — | ||
| Q1 24 | -117.4% | — |
每股收益（稀释后）AMBABEAM
| Q4 25 | $-0.35 | $2.53 | ||
| Q3 25 | $-0.47 | — | ||
| Q2 25 | $-0.58 | — | ||
| Q1 25 | $-0.48 | — | ||
| Q4 24 | $-0.58 | — | ||
| Q3 24 | $-0.85 | — | ||
| Q2 24 | $-0.93 | — | ||
| Q1 24 | $-1.51 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $174.1M | $1.2B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $590.1M | $1.2B |
| 总资产 | $751.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMBABEAM
| Q4 25 | $174.1M | $1.2B | ||
| Q3 25 | $142.7M | — | ||
| Q2 25 | $141.3M | — | ||
| Q1 25 | $144.6M | — | ||
| Q4 24 | $127.1M | — | ||
| Q3 24 | $153.9M | — | ||
| Q2 24 | $131.8M | — | ||
| Q1 24 | $144.9M | — |
股东权益AMBABEAM
| Q4 25 | $590.1M | $1.2B | ||
| Q3 25 | $576.5M | — | ||
| Q2 25 | $572.7M | — | ||
| Q1 25 | $561.4M | — | ||
| Q4 24 | $554.3M | — | ||
| Q3 24 | $547.6M | — | ||
| Q2 24 | $555.4M | — | ||
| Q1 24 | $559.9M | — |
总资产AMBABEAM
| Q4 25 | $751.9M | $1.5B | ||
| Q3 25 | $706.4M | — | ||
| Q2 25 | $701.9M | — | ||
| Q1 25 | $689.0M | — | ||
| Q4 24 | $670.8M | — | ||
| Q3 24 | $650.3M | — | ||
| Q2 24 | $638.7M | — | ||
| Q1 24 | $657.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.3M | $-83.3M |
| 自由现金流经营现金流 - 资本支出 | $31.4M | $-87.0M |
| 自由现金流率自由现金流/营收 | 29.0% | -76.3% |
| 资本支出强度资本支出/营收 | 2.7% | 3.3% |
| 现金转化率经营现金流/净利润 | — | -0.34× |
| 过去12个月自由现金流最近4个季度 | $64.3M | — |
8季度趋势，按日历期对齐
经营现金流AMBABEAM
| Q4 25 | $34.3M | $-83.3M | ||
| Q3 25 | $5.5M | — | ||
| Q2 25 | $14.8M | — | ||
| Q1 25 | $25.4M | — | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $16.7M | — | ||
| Q2 24 | $-15.0M | — | ||
| Q1 24 | $-4.0M | — |
自由现金流AMBABEAM
| Q4 25 | $31.4M | $-87.0M | ||
| Q3 25 | $1.4M | — | ||
| Q2 25 | $10.2M | — | ||
| Q1 25 | $21.2M | — | ||
| Q4 24 | $4.1M | — | ||
| Q3 24 | $14.2M | — | ||
| Q2 24 | $-16.1M | — | ||
| Q1 24 | $-6.0M | — |
自由现金流率AMBABEAM
| Q4 25 | 29.0% | -76.3% | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 11.9% | — | ||
| Q1 25 | 25.3% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -29.5% | — | ||
| Q1 24 | -11.6% | — |
资本支出强度AMBABEAM
| Q4 25 | 2.7% | 3.3% | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 5.3% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 3.7% | — |
现金转化率AMBABEAM
| Q4 25 | — | -0.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
